Search results for "recurrence"

showing 10 items of 1036 documents

Seismites resulting from high-frequency, high-magnitude earthquakes in Latvia caused by Late Glacial glacio-isostatic uplift

2016

Abstract Geologically extremely rapid changes in altitude by glacial rebound of the Earth crust after retreat of the Scandinavian Ice Sheet at the end of the last Weichselian glaciation influenced the palaeogeography of northern Europe. The uplift of the Earth crust apparently was not gradual, but shock-wise, as the uplift was accompanied by frequent, high-magnitude earthquakes. This can be deduced from strongly deformed layers which are interpreted as seismites. Such seismites have been described from several countries around the Baltic Sea, including Sweden, Germany and Poland. Now similarly deformed layers that must also be interpreted as seismites, have been discovered also in Latvia, a…

010506 paleontologygeographygeography.geographical_feature_categorySoft-sediment deformation structures (SSDS) SeismitesGeography Planning and DevelopmentMagnitude (mathematics)PaleontologyPost-glacial rebound010502 geochemistry & geophysics01 natural sciencesLatviaQE701-760PaleontologyTectonic upliftAltitudeEarthquake recurrence timeGlacio-isostatic reboundGlacial periodIce sheetWeichselian glaciationPalaeogeographySeismologyGeology0105 earth and related environmental sciencesEarth-Surface ProcessesJournal of Palaeogeography
researchProduct

Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion

2019

Background: Changes in the clinical subtype (CS) and intrinsic subtype (IS) between breast cancer (BC) metastases and corresponding primary tumours have been reported. However, their relationship with tumour genomic changes remains poorly characterised. Here, we analysed the association between genomic remodelling and subtype conversion in paired primary and metastatic BC samples. Methods: A total of 57 paired primary and metastatic tumours from GEICAM/2009-03 (ConvertHER, NCT01377363) study participants with centrally assessed CS (n = 57) and IS (n = 46) were analysed. Targeted capture and next-generation sequencing of 202 genes on formalin-fixed paraffin-embedded samples was performed. Th…

0301 basic medicineAdultCancer ResearchSkin NeoplasmsBioinformaticsBone NeoplasmsBreast Neoplasmsmedicine.disease_causeMetastatic tumours03 medical and health sciences0302 clinical medicineBreast cancerBreast cancermedicineBiomarkers TumorHumansProspective StudiesPAM50AgedAged 80 and overMutationIntrinsic subtypebusiness.industryHuman epidermal growth factorBrain NeoplasmsClonal architectureHigh-Throughput Nucleotide SequencingClonal remodellingMiddle Agedmedicine.diseasePrognosisGene Expression Regulation Neoplastic030104 developmental biologyOncology030220 oncology & carcinogenesisLymphatic MetastasisCancer cellMutationCancer researchFemaleNeoplasm Recurrence LocalClinical subtypeHeterogeneitybusinessHormoneFollow-Up Studies
researchProduct

Radiotherapy for the treatment of solitary plasmacytoma: 7-year outcomes by a mono-institutional experience.

2020

Objectives: Solitary plasmacytoma (SP) is characterized by a single mass of clonal plasma cells. Definitive RT can result in long-term local control of the SP. Due to the small number of patients and narrow range of doses, phase III randomized trials are lacking. The aim of this study is to further support the potential use of RT for the treatment of SP. Methods: Clinical data of all patients treated for SP at our Institution between 1992 and 2018 were reviewed. A total of 42 consecutive patients were analyzed. Results: The median follow-up was 84.8 months. Radiation dose did not differ significantly as a function of sex, type of SP (solitary bone plasmacytoma or as extramedullary plasmacyt…

0301 basic medicineAdultMaleCancer Researchmedicine.medical_specialtymedicine.medical_treatmentUrologySolitary plasmacytomaBone NeoplasmsMultiple myeloma; Plasma cell neoplasms; Radical radiotherapy; Solitary plasmacytomaEffective dose (radiation)law.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineHumansMultiple myelomaAgedRetrospective StudiesAged 80 and overHematologyRadical radiotherapyTumor sizebusiness.industryGeneral MedicinePlasma cell neoplasmMiddle Agedmedicine.diseasePrognosisSurvival AnalysisRadiation therapyPlasma cell neoplasm030104 developmental biologyTreatment OutcomeOncologyItaly030220 oncology & carcinogenesisDisease ProgressionFemalePlasma cell neoplasmsNeoplasm Recurrence LocalbusinessMultiple MyelomaSolitary plasmacytomaFollow-Up StudiesPlasmacytomaJournal of cancer research and clinical oncology
researchProduct

Double-Blind, Placebo-Controlled, Randomized Trial of Selenium in Graves Hyperthyroidism.

2017

Abstract Context Supplemental selenium (Se) may affect the clinical course of Graves disease (GD). Objective Evaluate efficacy of add-on Se on medical treatment in GD. Design Double-blind, placebo-controlled, randomized supplementation trial. Setting Academic endocrine outpatient clinic. Patients Seventy untreated hyperthyroid patients with GD. Intervention Additionally to methimazole (MMI), patients received for 24 weeks either sodium selenite 300 µg/d po or placebo. MMI was discontinued at 24 weeks in euthyroid patients. Main Outcome Measures Response rate (week 24), recurrence rate (week 36), and safety. Results A response was registered in 25 of 31 patients (80%) and in 27 of 33 (82%) a…

0301 basic medicineAdultMalemedicine.medical_specialtySide effectEndocrinology Diabetes and MetabolismGraves' diseaseClinical Biochemistry030209 endocrinology & metabolismContext (language use)PlaceboBiochemistryHyperthyroidismlaw.inventionPlacebos03 medical and health sciencesSelenium0302 clinical medicineEndocrinologyRandomized controlled trialDouble-Blind MethodlawRecurrenceInternal medicineMedicineOutpatient clinicHumansEuthyroidAdverse effectbusiness.industryBiochemistry (medical)Middle Agedmedicine.diseaseGraves Disease030104 developmental biologyEndocrinologyTreatment OutcomeDietary SupplementsFemalebusinessThe Journal of clinical endocrinology and metabolism
researchProduct

Annulate Lamellae in a Desmoplastic Small Round Cell Tumor

2016

0301 basic medicineAdultPathologymedicine.medical_specialtyOncogene ProteinsDesmoplastic small-round-cell tumorAnnulate lamellaOncogene Proteins FusionBiologyDesmoplastic Small Round Cell TumorPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineNeoplasm RecurrenceMicroscopy Electron TransmissionmedicineBiomarkers TumorHumansRetroperitoneal NeoplasmsReverse Transcriptase Polymerase Chain Reactionmedicine.diseaseImmunohistochemistryRetroperitoneal Neoplasm030104 developmental biology030220 oncology & carcinogenesisImmunohistochemistrySurgeryFemaleAnatomyNeoplasm Recurrence Local
researchProduct

Ovarian stimulation for oocyte vitrification does not modify disease-free survival and overall survival rates in patients with early breast cancer

2019

Research question: Does ovarian stimulation for oocyte vitrification affect disease-free survival and overall survival rates in women with early breast cancer? Design: This cohort study included 259 patients with early breast cancer; 148 patients underwent ovarian stimulation, whereas 111 patients did not. Patients were treated between January 2008 and December 2016. To calculate the disease-free survival time and overall survival rate, the time of definitive surgery was defined as the starting point. The follow-up was conducted up to 5 years. Results: Exposed and non-exposed groups were comparable in tumour, node and metastases classification, Nottingham grade, hormonal receptor status, tu…

0301 basic medicineAdultmedicine.medical_specialtyAdolescentDisease-free survivalStimulationBreast NeoplasmsKaplan-Meier EstimateOverall survival rateGastroenterologyDisease-Free Survival03 medical and health sciencesYoung Adult0302 clinical medicineBreast cancerBreast cancerOvulation InductionInternal medicinemedicineHumansFertility preservationProspective StudiesStage (cooking)Neoplasm MetastasisFertility preservationRetrospective StudiesCryopreservation030219 obstetrics & reproductive medicinebusiness.industryObstetrics and GynecologyFertility PreservationHistologymedicine.diseaseVitrificationConfidence intervalSurvival Rate030104 developmental biologyTreatment OutcomeReproductive MedicineOocytesFemaleOvarian stimulationNeoplasm Recurrence LocalbusinessDevelopmental BiologyCohort studyHormoneFollow-Up Studies
researchProduct

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer…

2016

Summary Background In the primary analysis of the NeoSphere trial, patients given neoadjuvant pertuzumab, trastuzumab, and docetaxel showed a significantly improved pathological complete response compared with those given trastuzumab and docetaxel after surgery. Here, we report 5-year progression-free survival, disease-free survival, and safety. Methods In this multicentre, open-label, phase 2 randomised trial in hospitals and medical clinics, treatment-naive adults with locally advanced, inflammatory, or early-stage HER2-positive breast cancer were randomly assigned (1:1:1:1) to receive four neoadjuvant cycles of trastuzumab (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) plus do…

0301 basic medicineAdultmedicine.medical_specialtyTime FactorsAdolescentReceptor ErbB-2PopulationAntibodies Monoclonal HumanizedGastroenterologyGroup B03 medical and health sciencesYoung Adult0302 clinical medicineInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumanseducationSurvival rateAgedNeoplasm StagingAged 80 and overeducation.field_of_studybusiness.industryMiddle AgedTrastuzumabmedicine.diseasePrognosisNeoadjuvant TherapySurgerySurvival Rate030104 developmental biologyOncologyDocetaxelTolerabilityChemotherapy Adjuvant030220 oncology & carcinogenesisFemaleInflammatory Breast NeoplasmsPertuzumabNeoplasm Recurrence LocalbusinessFebrile neutropeniamedicine.drugEpirubicinFollow-Up StudiesThe Lancet. Oncology
researchProduct

Chemoprevention and therapeutic role of essential oils and phenolic compounds: Modeling tumor microenvironment in glioblastoma

2021

Glioblastoma (GBM) is the most common primary tumor of the central nervous system. Current treatments available for GBM entails surgical resection followed by temozolomide chemotherapy and/or radiotherapy, which are associated with multidrug resistance and severe side effects. While this treatment could yield good results, in almost all cases, patients suffer from relapse, which leads to reduced survival rates. Thus, therapeutic approaches with improved efficiency and reduced off-target risks are needed to overcome these problems. Regarding this, natural products appear as a safe and attractive strategy as chemotherapeutic agents or adjuvants in the treatment of GBM. Besides the increasing …

0301 basic medicineAngiogenesismedicine.medical_treatmentAntineoplastic AgentsMetastasis03 medical and health sciences0302 clinical medicinePhenolsOils VolatileTumor MicroenvironmentAnimalsHumansMedicinePharmacologyBiological ProductsChemotherapyTumor microenvironmentTemozolomideBrain Neoplasmsbusiness.industrymedicine.diseasePrimary tumorRadiation therapy030104 developmental biology030220 oncology & carcinogenesisCancer researchNeoplasm Recurrence LocalStem cellGlioblastomabusinessmedicine.drugPharmacological Research
researchProduct

Gut vascular barrier impairment leads to intestinal bacteria dissemination and colorectal cancer metastasis to liver

2021

Metastasis is facilitated by the formation of a "premetastatic niche," which is fostered by primary tumor-derived factors. Colorectal cancer (CRC) metastasizes mainly to the liver. We show that the premetastatic niche in the liver is induced by bacteria dissemination from primary CRC. We report that tumor-resident bacteria Escherichia coli disrupt the gut vascular barrier (GVB), an anatomical structure controlling bacterial dissemination along the gut-liver axis, depending on the virulence regulator VirF. Upon GVB impairment, bacteria disseminate to the liver, boost the formation of a premetastatic niche, and favor the recruitment of metastatic cells. In training and validation cohorts of C…

0301 basic medicineCancer ResearchColorectal cancerRegulatorVirulencemedicine.disease_causeMetastasis03 medical and health sciences0302 clinical medicinemedicineHumansNeoplasm MetastasisEscherichia coliBacteriabiologybusiness.industryLiver NeoplasmsDistant recurrencebiology.organism_classificationmedicine.disease030104 developmental biologyLiverOncology030220 oncology & carcinogenesisColonic NeoplasmsCancer researchIntestinal bacteriaNeoplasm Recurrence LocalColorectal NeoplasmsbusinessBacteriaCancer Cell
researchProduct

Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation

2020

AbstractPurpose:Despite the therapeutic success of existing HER2-targeted therapies, tumors invariably relapse. This study aimed at identifying new mechanisms responsible for HER2-targeted therapy resistance.Experimental Design:We have used a platform of HER2-targeted therapy–resistant cell lines and primary cultures of healthy and tumor-associated fibroblasts (TAF) to identify new potential targets related to tumor escape from anti-HER2 therapies.Results:We have shown that TAFs promote resistance to HER2-targeted therapies. TAFs produce and secrete high levels of FGF5, which induces FGFR2 activation in the surrounding breast cancer cells. FGFR2 transactivates HER2 via c-Src, leading to res…

0301 basic medicineCancer ResearchReceptor ErbB-2medicine.medical_treatmentMice NudeBreast NeoplasmsDrug resistanceTargeted therapy03 medical and health sciencesMice0302 clinical medicineBreast cancerCancer-Associated FibroblastsTrastuzumabCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsmedicineNeoplasmAnimalsHumansReceptor Fibroblast Growth Factor Type 2skin and connective tissue diseasesneoplasmsbusiness.industryLapatinibTrastuzumabmedicine.diseaseXenograft Model Antitumor AssaysSurvival Rate030104 developmental biologyOncologyTumor EscapeApoptosisDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer researchFemaleSignal transductionNeoplasm Recurrence Localbusinessmedicine.drugSignal Transduction
researchProduct